The shares of Lucira Health Inc. (NASDAQ: LHDX) rose 12.57% to $9.40 in premarket trading at the last check. Thursday’s session closed with Lucira stock down -7.02% at $8.35. LHDX stock volume stayed at 0.45 million shares, slightly below the average daily volume of 0.51K in the past 50 days.
LHDX stock went down by -30.99% in the last week. The current market capitalization of Lucira is $326.15 million, and the number of outstanding shares of LHDX stands at 39.06 million. News of successful identification of a COVID-variant sends LHDX stock soaring.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Lucira’s success in brief:
The medical technology company Lucira Health focuses on the development and commercialization of transformative and innovative diagnostics for infectious diseases. In a single-use, consumer-friendly, palm-sized test kit powered by two AA batteries, LHDX’s testing platform produces lab-quality molecular testing. Test kits from LHDX provide accurate, reliable, and on-the-spot results. LUCIRA COVID-19 All-In-One Test Kits (RX) provides results within 30 minutes of the time samples are taken.
Today, Lucira Health confirmed that its Lucira molecular test kit can identify COVID-19’s double mutant variant.
- On March 24, 2021, researchers first identified the “double mutant” variant in India, and on March 25, 2021, Stanford Clinical Virology Lab scientists found the same variant in California.
- CDC scientists are tracking its two genetic mutation sequences that are unique among other variants.
- Debkishore Mitra, co-founder and chief technology officer, LHDX, said viruses ‘copy’ themselves when they replicate.
- A number of these strains were first discovered in England, Brazil and South Africa.
- Different variants can occur when the virus manifests its genetic code and it copies itself and creates a new, mutant code.
- By making errors in identifying, the immune system isn’t able to counteract the virus and it will become harder to detect.
How is the LHDX test kit different?
A simple ‘swab, stir, and detect’ platform available via Lucira (LHDX) demonstrated that a hundred percent of users were able to complete the test in less than two minutes of hands-on time. In contrast, to test kit from LHDX, lab tests conducted in centralized laboratories take up to 14 days to produce similar accurate tests results.
